BR112015017650A2 - composição compreendendo um antagomir encapsulado - Google Patents

composição compreendendo um antagomir encapsulado

Info

Publication number
BR112015017650A2
BR112015017650A2 BR112015017650A BR112015017650A BR112015017650A2 BR 112015017650 A2 BR112015017650 A2 BR 112015017650A2 BR 112015017650 A BR112015017650 A BR 112015017650A BR 112015017650 A BR112015017650 A BR 112015017650A BR 112015017650 A2 BR112015017650 A2 BR 112015017650A2
Authority
BR
Brazil
Prior art keywords
composition
encapsulated
antagonist
inhibitor
relates
Prior art date
Application number
BR112015017650A
Other languages
English (en)
Inventor
Perez Amadeo
David Garcia-Dorado Garcia Antonio
Rodriguez Sinovas Antonio
Ferret Eulalia
Barba Vert Ignasi
Asin Miguel-Angel
Bellera Gotarda Neus
Original Assignee
Fundacio Hospital Univ Vall Dhebron Institut De Recerca
Pierre Fabre Medicament S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Hospital Univ Vall Dhebron Institut De Recerca, Pierre Fabre Medicament S A S filed Critical Fundacio Hospital Univ Vall Dhebron Institut De Recerca
Publication of BR112015017650A2 publication Critical patent/BR112015017650A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1/1 resumo “composição compreendendo um antagomir encapsulado” a invenção diz respeito a uma composição compreendendo uma quantidade eficaz de pelo menos um inibidor de um mirna envolvido na angiogênese, ou um precursor do mesmo, em que o dito inibidor é microencapsulado dentro de microesferas poliméricas biodegradáveis e biocompatíveis. a invenção também diz respeito ao uso da dita composição para prevenir ou tratar distúrbios cardíacos, incluindo distúrbios cardíacos causados pela isquemia.
BR112015017650A 2013-01-24 2014-01-23 composição compreendendo um antagomir encapsulado BR112015017650A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir
PCT/IB2014/058500 WO2014115103A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Publications (1)

Publication Number Publication Date
BR112015017650A2 true BR112015017650A2 (pt) 2017-11-21

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015017650A BR112015017650A2 (pt) 2013-01-24 2014-01-23 composição compreendendo um antagomir encapsulado

Country Status (16)

Country Link
US (1) US20150352055A1 (pt)
EP (2) EP2759595B1 (pt)
JP (1) JP2016506923A (pt)
KR (1) KR20160018451A (pt)
CN (1) CN105229151A (pt)
AU (1) AU2014208419A1 (pt)
BR (1) BR112015017650A2 (pt)
CA (1) CA2898958A1 (pt)
ES (2) ES2606636T3 (pt)
HK (1) HK1219753A1 (pt)
HU (1) HUE032125T2 (pt)
MX (1) MX2015009323A (pt)
PL (1) PL2759595T3 (pt)
RU (1) RU2668794C2 (pt)
WO (1) WO2014115103A1 (pt)
ZA (1) ZA201505602B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EA201791644A1 (ru) * 2015-01-20 2018-01-31 Мираджен Терапьютикс, Инк. Ингибиторы mir-92 и их применение
WO2018183127A1 (en) * 2017-03-25 2018-10-04 MiRagen Therapeutics, Inc. Mir-92 inhibitors for treatment of heart failure
WO2020183718A1 (ja) * 2019-03-14 2020-09-17 エム・テクニック株式会社 Ｐｌｇａ微粒子、その徐放性製剤及びその製造方法
CN110484537B (zh) * 2019-09-02 2021-07-27 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P（Asp-AP）-ANTAGOMIR-RNA微球
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
CN111729088B (zh) * 2020-08-21 2020-12-15 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
CA2533701A1 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
EP2623598B1 (en) * 2007-10-04 2018-08-01 Roche Innovation Center Copenhagen A/S Micromirs
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
CN102481310A (zh) * 2009-05-20 2012-05-30 得克萨斯系统大学董事会 牵涉心肌梗死后重塑和心力衰竭的微小rna的鉴定

Also Published As

Publication number Publication date
CA2898958A1 (en) 2014-07-31
US20150352055A1 (en) 2015-12-10
RU2668794C2 (ru) 2018-10-02
ES2606636T3 (es) 2017-03-24
CN105229151A (zh) 2016-01-06
HUE032125T2 (en) 2017-08-28
PL2759595T3 (pl) 2017-09-29
RU2015134770A (ru) 2017-03-03
KR20160018451A (ko) 2016-02-17
WO2014115103A1 (en) 2014-07-31
MX2015009323A (es) 2016-04-04
EP2759595A1 (en) 2014-07-30
ZA201505602B (en) 2017-05-31
EP2759595B1 (en) 2016-09-14
JP2016506923A (ja) 2016-03-07
EP2948551B1 (en) 2018-05-02
EP2948551A1 (en) 2015-12-02
HK1219753A1 (zh) 2017-04-13
AU2014208419A1 (en) 2015-08-13
ES2688160T3 (es) 2018-10-31

Similar Documents

Publication Publication Date Title
BR112015017650A2 (pt) composição compreendendo um antagomir encapsulado
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
DOP2018000182A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
BR112017017217A2 (pt) ?composição que compreende ramnolipídeo e siloxano?
BR112016013299A2 (pt) Composto
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112013030599A2 (pt) núcleo absorvente para artigos absorventes descartáveis
BR112012027279A2 (pt) composições de emulsão farmacêutica com baixo teor de óleo que compreendem progestogênio
BR112015013684A2 (pt) estruturante melhorado com fios de agentes estruturantes contendo hidroxila, cristalinos, não poliméricos
BR112016021648A2 (pt) novos compostos
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
BR112016021282A8 (pt) processos para a preparação de compostos antifúngicos e os referidos compostos
BR112016006388A2 (pt) inibidor seletivo da fosfatidilinositol 3-quinase gama
BR112015029987A8 (pt) Beta-caseína a2 e a prevenção de inflamação do intestino
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112016007068A2 (pt) ?composições cosméticas?
CR20160309A (es) Inhibidores de serina/treonina cinasa
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
BR112015005694A2 (pt) pró-fármacos de inibidor amino-quinazoliníco de quinase
BR112017021527A2 (pt) dentifrícios com base em cálcio para acentuar absorção de ingredientes ativos.
NI201600006A (es) Pirazolo-piridinaminas sustituidas
BR112016013316A8 (pt) método para a produção de furfural e uso de ácido metanossulfônico
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112015032029A2 (pt) uso de uma composição compreendendo óleo de peixe e suco para o tratamento de inflamação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.